Literature DB >> 15738027

Risk factors for young premenopausal women with endometrial cancer.

Pamela T Soliman1, Jonathan C Oh, Kathleen M Schmeler, Charlotte C Sun, Brian M Slomovitz, David M Gershenson, Thomas W Burke, Karen H Lu.   

Abstract

OBJECTIVE: Endometrial cancer is the most common gynecologic malignancy in the United States. The mean age at diagnosis is 61 years; however, 5-30% of women are aged younger than 50 years at the time of diagnosis. The objective of this study was to conduct a clinical and pathologic review of endometrial cancers diagnosed in premenopausal women aged younger than 50 years, to better identify the risk factors for this subgroup of women.
METHODS: We conducted a retrospective cohort study of patients with histologically confirmed endometrial cancer treated at the University of Texas, M. D. Anderson Cancer Center from 1989 to 2003. Clinical characteristics including age, body mass index (BMI), parity, diabetes, and personal or family history of cancer were obtained from the medical record. Pathologic information was obtained from pathology reports.
RESULTS: Twelve percent (188/1531) of all patients with endometrial adenocarcinoma were aged younger than 50 years. The mean age at diagnosis was 41 years (range 21-49 years). Mean BMI was 34 kg/m(2) (range 18-68); 58% of patients had a BMI of 30 or greater. Fifty-five percent were nulliparous and 39% reported irregular menstrual cycles. The incidence of both diabetes and hypertension was 23%. Thirty-six patients (19%) had synchronous ovarian cancers.
CONCLUSION: We found that the majority of patients diagnosed with endometrial cancer at a young age were obese and nulliparous. In addition, we found a high incidence of synchronous primary ovarian cancers in this cohort of young, premenopausal women.

Entities:  

Mesh:

Year:  2005        PMID: 15738027     DOI: 10.1097/01.AOG.0000154151.14516.f7

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  65 in total

1.  Loss of inhibitory insulin receptor substrate-1 phosphorylation is an early event in mammalian target of rapamycin-dependent endometrial hyperplasia and carcinoma.

Authors:  Adrienne S McCampbell; Heather A Harris; Judy S Crabtree; Richard C Winneker; Cheryl L Walker; Russell R Broaddus
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

2.  Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.

Authors:  A S McCampbell; M L Mittelstadt; R Dere; S Kim; L Zhou; B Djordjevic; P T Soliman; Q Zhang; C Wei; S D Hursting; K H Lu; R R Broaddus; C L Walker
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

3.  Racial disparities in young women with endometrial cancer.

Authors:  Barenya Mukerji; Caitlin Baptiste; Ling Chen; Ana I Tergas; June Y Hou; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2018-01-05       Impact factor: 5.482

Review 4.  Interplay between insulin resistance and estrogen deficiency as co- activators in carcinogenesis.

Authors:  Zsuzsanna Suba
Journal:  Pathol Oncol Res       Date:  2011-10-09       Impact factor: 3.201

5.  Incidence and factors associated with synchronous ovarian and endometrial cancer: a population-based case-control study.

Authors:  M M AlHilli; S C Dowdy; A L Weaver; J L St Sauver; G L Keeney; A Mariani; K C Podratz; J N Bakkum-Gamez
Journal:  Gynecol Oncol       Date:  2011-12-28       Impact factor: 5.482

6.  Restoration of microRNA-29c in type I endometrioid cancer reduced endometrial cancer cell growth.

Authors:  Michelle Van Sinderen; Meaghan Griffiths; Ellen Menkhorst; Keith Niven; Evdokia Dimitriadis
Journal:  Oncol Lett       Date:  2019-07-09       Impact factor: 2.967

7.  Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.

Authors:  Navdeep Pal; Russell R Broaddus; Diana L Urbauer; Nyla Balakrishnan; Andrea Milbourne; Kathleen M Schmeler; Larissa A Meyer; Pamela T Soliman; Karen H Lu; Pedro T Ramirez; Lois Ramondetta; Diane C Bodurka; Shannon N Westin
Journal:  Obstet Gynecol       Date:  2018-01       Impact factor: 7.661

Review 8.  Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases.

Authors:  Mi-La Kim; Seok Ju Seong
Journal:  Obstet Gynecol Sci       Date:  2013-03-12

9.  Fibulin-5 localisation in human endometrial cancer shifts from epithelial to stromal with increasing tumour grade, and silencing promotes endometrial epithelial cancer cell proliferation.

Authors:  Amy Louise Winship; Kate Rainczuk; Amanda Ton; Eva Dimitriadis
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

10.  Histopathology of women with non-uniform endometrial echogenicity and risk factors for atypical endometrial hyperplasia and carcinoma.

Authors:  Qing Cong; Lingxiao Luo; Zhongpeng Fu; Jiaqi Lu; Wei Jiang; Long Sui
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.